Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Buys 47,537 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost acquired 47,537 shares of OPKO Health stock in a transaction that occurred on Tuesday, January 28th. The shares were purchased at an average cost of $1.47 per share, with a total value of $69,879.39. Following the purchase, the chief executive officer now owns 213,234,014 shares of the company’s stock, valued at $313,454,000.58. This represents a 0.02 % increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, January 17th, Phillip Md Et Al Frost acquired 150,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.47 per share, with a total value of $220,500.00.
• On Wednesday, January 15th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.48 per share, with a total value of $740,000.00.
• On Friday, December 13th, Phillip Md Et Al Frost acquired 125,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.59 per share, with a total value of $198,750.00.
• On Wednesday, December 11th, Phillip Md Et Al Frost acquired 500,000 shares of OPKO Health stock. The shares were purchased at an average cost of $1.56 per share, with a total value of $780,000.00.
• On Friday, November 29th, Phillip Md Et Al Frost acquired 199,072 shares of OPKO Health stock. The shares were purchased at an average cost of $1.53 per share, with a total value of $304,580.16.
• On Friday, November 22nd, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.59 per share, with a total value of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost purchased 100,000 shares of OPKO Health stock. The stock was bought at an average cost of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was bought at an average cost of $1.50 per share, with a total value of $420,274.50.

OPKO Health Price Performance

Shares of OPKO Health stock opened at $1.51 on Friday. OPKO Health, Inc. has a 52-week low of $0.86 and a 52-week high of $1.76. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -7.95 and a beta of 1.63. The company has a fifty day moving average of $1.52 and a 200-day moving average of $1.52. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97.

OPKO Health (NASDAQ:OPK) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.03 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.13. The business had revenue of $173.60 million during the quarter, compared to analysts’ expectations of $181.32 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. During the same quarter in the prior year, the company posted ($0.11) EPS. Equities research analysts expect that OPKO Health, Inc. will post -0.25 EPS for the current year.

Institutional Investors Weigh In On OPKO Health

Institutional investors have recently added to or reduced their stakes in the company. FMR LLC boosted its position in OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 11,089 shares during the period. Orion Portfolio Solutions LLC purchased a new stake in OPKO Health during the 3rd quarter valued at $45,000. Algert Global LLC purchased a new stake in shares of OPKO Health in the 2nd quarter worth about $44,000. Private Advisor Group LLC lifted its position in shares of OPKO Health by 242.7% in the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 25,000 shares during the period. Finally, World Investment Advisors LLC purchased a new stake in shares of OPKO Health in the 3rd quarter worth about $61,000. Hedge funds and other institutional investors own 64.63% of the company’s stock.

Analyst Upgrades and Downgrades

OPK has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a research note on Wednesday, January 8th. Barrington Research reaffirmed an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Friday, November 8th. Finally, StockNews.com cut shares of OPKO Health from a “hold” rating to a “sell” rating in a research note on Wednesday, January 15th.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.